Online inquiry

IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ840MR)

This product GTTS-WQ840MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CD276 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001024736.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 80381
UniProt ID Q5ZPR3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ840MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ629MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ3398MR IVTScrip™ mRNA-Anti-ALB, aALB03(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA aALB03
GTTS-WQ13072MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-00547659
GTTS-WQ7300MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FPA-008
GTTS-WQ14409MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ3962MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ13112MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-03446962
GTTS-WQ10900MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MABp1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW